Septerna (NASDAQ:SEPN) Downgraded to “Buy” Rating by Wall Street Zen

Septerna (NASDAQ:SEPN) was downgraded by equities research analysts at Wall Street Zen from a “strong-buy” rating to a “buy” rating in a research report issued on Saturday.

A number of other analysts have also issued reports on the company. Truist Financial initiated coverage on Septerna in a report on Monday, December 15th. They issued a “buy” rating and a $34.00 target price on the stock. Wells Fargo & Company raised Septerna from an “equal weight” rating to an “overweight” rating and increased their price objective for the company from $18.00 to $28.00 in a research report on Friday, November 14th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Septerna in a research report on Wednesday, October 8th. Jones Trading initiated coverage on shares of Septerna in a research note on Tuesday, December 23rd. They set a “buy” rating and a $43.00 target price for the company. Finally, HC Wainwright increased their price target on shares of Septerna from $26.00 to $30.00 and gave the company a “buy” rating in a report on Tuesday, November 11th. One analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Septerna presently has a consensus rating of “Moderate Buy” and a consensus price target of $33.00.

Septerna Trading Down 1.7%

Shares of Septerna stock opened at $25.30 on Friday. The firm has a fifty day simple moving average of $25.39 and a 200-day simple moving average of $18.68. The stock has a market capitalization of $1.13 billion, a price-to-earnings ratio of -16.75 and a beta of 3.85. Septerna has a 1-year low of $4.17 and a 1-year high of $30.50.

Septerna (NASDAQ:SEPN) last announced its earnings results on Monday, November 10th. The company reported ($0.09) EPS for the quarter, missing the consensus estimate of $0.19 by ($0.28). Septerna had a negative return on equity of 17.98% and a negative net margin of 266.77%.The firm had revenue of $21.50 million during the quarter, compared to the consensus estimate of $24.50 million. As a group, research analysts predict that Septerna will post -7.11 earnings per share for the current year.

Insider Buying and Selling

In other Septerna news, SVP Daniel D. Long sold 3,501 shares of Septerna stock in a transaction on Monday, November 10th. The shares were sold at an average price of $18.06, for a total transaction of $63,228.06. Following the sale, the senior vice president owned 92,911 shares in the company, valued at $1,677,972.66. The trade was a 3.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 4.30% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Septerna

A number of hedge funds and other institutional investors have recently made changes to their positions in SEPN. Russell Investments Group Ltd. acquired a new stake in shares of Septerna during the 3rd quarter valued at about $36,000. Covestor Ltd lifted its stake in Septerna by 55.8% during the third quarter. Covestor Ltd now owns 3,620 shares of the company’s stock worth $68,000 after purchasing an additional 1,296 shares during the period. BNP Paribas Financial Markets boosted its holdings in Septerna by 88.0% during the third quarter. BNP Paribas Financial Markets now owns 4,155 shares of the company’s stock valued at $78,000 after purchasing an additional 1,945 shares in the last quarter. JPMorgan Chase & Co. boosted its holdings in Septerna by 15.0% during the second quarter. JPMorgan Chase & Co. now owns 10,101 shares of the company’s stock valued at $107,000 after purchasing an additional 1,315 shares in the last quarter. Finally, PharVision Advisers LLC bought a new stake in shares of Septerna in the 2nd quarter valued at approximately $107,000.

Septerna Company Profile

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.